TLR4- and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 3, 2015, Pages 110.e19-110.e27

  Olbert, Peter J ^a   Kesch, Claudia ^a   Henrici, Marcus ^a   Subtil, Florentine S ^a   Honacker, Astrid ^a   Hegele, Axel ^a   Hofmann, Rainer ^a   Hänze, Jörg ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Bladder cancer; Cell viability; Immunotherapy; Invasion; TLR4; TLR9

Indexed keywords

BCG VACCINE; BETA INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MESSENGER RNA; METHYL CPG BINDING PROTEIN; PLACENTAL GROWTH FACTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; OLIGODEOXYRIBONUCLEOTIDE; TLR4 PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN;

ARTICLE; BLADDER CANCER CELL LINE; CANCER GROWTH; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; WESTERN BLOTTING; ADJUVANT CHEMOTHERAPY; BLADDER TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOTHERAPY; INNATE IMMUNITY; METABOLISM; TUMOR CELL LINE;

BCG VACCINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTHERAPY, ADJUVANT; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; LIPOPOLYSACCHARIDES; NEOPLASM INVASIVENESS; OLIGODEOXYRIBONUCLEOTIDES; RNA, MESSENGER; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; URINARY BLADDER NEOPLASMS;

EID: 84925365087     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.09.016     Document Type: Article

References (29)

1. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011, 59:997-1008.
2. Heldwein K.A., Liang M.D., Andresen T.K., et al. TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J Leukoc Biol 2003, 74:277-286.
3. Tsuji S., Matsumoto M., Takeuchi O., et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guerin: involvement of toll-like receptors. Infect Immun 2000, 68:6883-6890.
4. von Meyenn F., Schaefer M., Weighardt H., et al. Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guerin by Flt3-ligand generated dendritic cells. Immunobiology 2006, 211:557-565.
5. McGettrick A.F., O'Neill L.A. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br J Haematol 2007, 139:185-193.
6. Kopp E., Medzhitov R. Recognition of microbial infection by toll-like receptors. Curr Opin Immunol 2003, 15:396-401.
7. Vora P., Youdim A., Thomas L.S., et al. Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol 2004, 173:5398-5405.
8. Yu L., Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother 2008, 57:1271-1278.
9. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397.
10. Poltorak A., He X., Smirnova I., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
11. Andreani V., Gatti G., Simonella L., Rivero V., Maccioni M. Activation of toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res 2007, 67:10519-10527.
12. He W., Liu Q., Wang L., Chen W., Li N., Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 2007, 44:2850-2859.
13. Huang B., Zhao J., Li H., et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005, 65:5009-5014.
14. Jing Y.Y., Han Z.P., Sun K., et al. Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide. BMC Med 2012, 10:98.
15. Krieg A.M. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep 2004, 6:88-95.
16. Hemmi H., Takeuchi O., Kawai T., et al. A toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
17. Vollmer J., Weeratna R., Payette P., et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004, 34:251-262.
18. Ilvesaro J.M., Merrell M.A., Li L., et al. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res 2008, 6:1534-1543.
19. Ilvesaro J.M., Merrell M.A., Swain T.M., et al. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007, 67:774-781.
20. Merrell M.A., Ilvesaro J.M., Lehtonen N., et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 2006, 4:437-447.
21. Tanaka J., Sugimoto K., Shiraki K., et al. Functional cell surface expression of toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas. Int J Oncol 2010, 37:805-814.
22. Wang C., Cao S., Yan Y., et al. TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer 2010, 10:415.
23. Hegele A., Dalpke A., Barth P., et al. Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model. Anticancer Res 2004, 24:2225-2230.
24. Olbert P.J., Schrader A.J., Simon C., et al. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall. Anticancer Res 2009, 29:2067-2076.
25. Ayari C., Bergeron A., LaRue H., Menard C., Fradet Y. Toll-like receptors in normal and malignant human bladders. J Urol 2011, 185:1915-1921.
26. Okamoto M., Hattori K., Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 1997, 72:149-154.
27. Szlosarek P., Charles K.A., Balkwill F.R. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006, 42:745-750.
28. Damiano V., Caputo R., Garofalo S., et al. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A 2007, 104:12468-12473.
29. Nurmenniemi S., Kuvaja P., Lehtonen S., et al. Toll-like receptor 9 ligands enhance mesenchymal stem cell invasion and expression of matrix metalloprotease-13. Exp Cell Res 2010, 316:2676-2682.